Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.896 EUR | -0.63% | -3.27% | -17.21% |
Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Apr. 03 | Tana Oy announced that it has received funding from CapMan Oyj | CI |
Sales 2024 * | 70.3M 74.74M | Sales 2025 * | 79.47M 84.48M | Capitalization | 337M 358M |
---|---|---|---|---|---|
Net income 2024 * | 22M 23.39M | Net income 2025 * | 33M 35.08M | EV / Sales 2024 * | 5.5 x |
Net Debt 2024 * | 50.17M 53.33M | Net Debt 2025 * | 37.83M 40.22M | EV / Sales 2025 * | 4.71 x |
P/E ratio 2024 * |
14.6
x | P/E ratio 2025 * |
9.72
x | Employees | 200 |
Yield 2024 * |
5.94% | Yield 2025 * |
8.04% | Free-Float | 65.89% |
Latest transcript on CapMan Oyj
1 week | -4.31% | ||
Current month | -1.45% | ||
1 month | -1.45% | ||
3 months | -15.20% | ||
6 months | -18.11% | ||
Current year | -16.68% |
Managers | Title | Age | Since |
---|---|---|---|
Pia Kåll
CEO | Chief Executive Officer | 44 | 23-03-14 |
Joakim Frimodig
CHM | Chairman | 46 | 15-12-31 |
Atte Rissanen
DFI | Director of Finance/CFO | 37 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Johan Bygge
BRD | Director/Board Member | 68 | 21-03-16 |
Director/Board Member | 67 | 19-03-12 | |
Director/Board Member | 55 | 20-03-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.896 | -0.63% | 102 211 |
24-04-18 | 1.908 | 0.00% | 51,550 |
24-04-17 | 1.908 | -0.63% | 133,422 |
24-04-16 | 1.92 | -1.64% | 67,262 |
24-04-15 | 1.952 | -0.41% | 74,920 |
Delayed Quote Nasdaq Helsinki, April 18, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.68% | 359M | |
-0.82% | 34.3B | |
+1.61% | 31.43B | |
+6.33% | 5.51B | |
+0.10% | 3.09B | |
+9.93% | 2.85B | |
+10.85% | 2.62B | |
-17.62% | 2.28B | |
+4.52% | 1.24B | |
-3.38% | 1.05B |
- Stock Market
- Equities
- CAPMAN Stock